Tissue microarrays: applications in urological cancer research

Merseburger, Axel S.; Anastasiadis, Aristotelis G.; Hennenlotter, Joerg; Schilling, Dieter; Simon, Perikles; Machtens, S.; Serth, J.; Stenzl, Arnulf; Kuczyk, Markus A.

doi:10.1007/s00345-006-0103-1

Cited by 11 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hematoxylin and eosin staining was performed for each tumor specimen to validate tumor stage and grade. Tissue microarrays (TMAs) were constructed and stained as previously described (17,(19)(20)(21). A commercially available Maspin antibody (monoclonal mouse antibody; NCL-Maspin, Novocastra Laboratories Ltd.) in a dilution of 1:500 was used.…”

Section: Tissue Microarray and Immunohistochemical Analysismentioning

confidence: 99%

Maspin protein expression correlates with tumor progression in non-muscle invasive bladder cancer

Kramer

Waalkes²,

Hennenlotter³

et al. 2010

Oncology Letters

View full text Add to dashboard Cite

Abstract. Maspin is a 42-kDa protein that belongs to the family of serine protease inhibitors. It is involved in various physiological processes. In cancer tissue, Maspin was found to influence angiogenesis, tumor growth, metastasis and the prognosis of tumor patients. This study was performed to analyze the involvement of Maspin in transitional cell carcinoma of the bladder as well as its prognostic impact in a large patient cohort. Specimens from 162 non-muscle invasive bladder cancer patients (pTa, 91; pT1, 71) treated by transurethral resection with a minimum 3-year follow-up (median 58.5 months) were included in the present investigation. Tissue microarrays were constructed, and the specimens were immunohistochemically stained for Maspin protein expression. Each tissue specimen was assessed on a staining scale ranging from 0 (no staining) to 300 (strong staining) and correlated with various clinicopathological parameters. Maspin protein expression predicted progression with a sensitivity of 95% and a specificity of 70% (p<0.001). In predicting recurrence, Maspin staining showed 52% sensitivity and 67% specificity (p<0.05). Kaplan-Meier analyses were performed, and a low Maspin protein expression was correlated with a higher incidence of tumor progression (p<0.0001). However, expression levels of Maspin protein did not distinguish between pTa and pT1 specimens. Multivariate analyses indicated Maspin expression as an independent factor for predicting progression (p<0.0001) and recurrence (p<0.05). The present results suggest that the Maspin protein expression is an independent prognostic indicator for predicting recurrence and progression to muscle invasive disease. This study further emphasizes a possible clinical role of this novel tumor suppressor gene in transitional cell carcinoma of the bladder.

show abstract

Section: Tissue Microarray and Immunohistochemical Analysismentioning

confidence: 99%

Maspin protein expression correlates with tumor progression in non-muscle invasive bladder cancer

Kramer

Waalkes²,

Hennenlotter³

et al. 2010

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Biomarkers are either prognostic, predictive, or surrogate markers, or they may have a combination of these characteristics. A prognostic biomarker provides evidence for a patient's potential outcome from a disease independent of therapy, whereas predictive biomarkers estimate the likelihood of response/benefit to a specific therapy [65,66]. Most biomarkers reported in mCRPC are prognostic rather than predictive (reviewed by Armstrong et al [64]).…”

Section: Making Treatment Decisions In the Management Of Metastatic Crpcmentioning

confidence: 99%

Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer

Merseburger¹,

Bellmunt²,

Jenkins³

et al. 2013

The Oncologist

View full text Add to dashboard Cite

The arrival of several new agents-cabazitaxel, abiraterone acetate, enzalutamide, and radium-223-is changing the treatment options and management of patients with metastatic castration-resistant prostate cancer (mCRPC). Many other novel agents are also being investigated. As new drugs become approved, new treatment strategies and markers to best select which patients will best respond to which drug are needed. This review article is a summary of a European Treatment Practices Meeting, which was convened to discuss these latest data on novel agents and current treatment strategies in the mCRPC setting.

show abstract

“…Uno de los avances introducidos en la metodología para el estudio de la expresión de estos marcadores en el tejido tumoral ha sido el "tissue microarray o microarray de tejido" (TMA). Esta nueva tecnología está permitiendo el análisis de la expresión de un gen, simultáneamente en varios tejidos procedentes de muchos tumores distintos 95 pudiendo efectuarse el análisis de expresión mediante técnicas de inmunohistoquímica, hibridización in situ, FISH y CISH, con un menor coste y una mayor rapidez 96 . El análisis de marcadores moleculares pronósticos en tejido tumoral prostático clásicamente ha sido efectuados sobre líneas celulares y en material procedente de prostatectomías, evaluando principalmente la expresión de proteínas mediante técnicas de inmunohistoquímica.…”

Section: Marcadores Moleculares Pronósticos En La Biopsia Prostáticaunclassified

Factores pronósticos y predictivos del carcinoma de próstata en la biopsia prostática

Ramírez¹

2007

Actas Urológicas Españolas

View full text Add to dashboard Cite

This paper reviews the morphological cancer diagnosis criteria on needle biopsies, the predictive meaning of the pathological lesions of HGPIN, HAA, and P.I.A and the peculiar histopathological patterns in prostatic adenocarcinoma. We present the histological parameters that the pathologist has to informe in the diagnositic, on the routine prostate needle biopsy: Gleason histological degree, histological type, number of invaded cilindres, percentage of tumor in each cylinder, location of the biopsy and ymphovascular invasion. We also emphasize the importance of new predictive biomarkers nowadays in study and probably involved in tumor progression.

show abstract

Tissue microarrays: applications in urological cancer research

Cited by 11 publications

References 17 publications

Maspin protein expression correlates with tumor progression in non-muscle invasive bladder cancer

Maspin protein expression correlates with tumor progression in non-muscle invasive bladder cancer

Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer

Factores pronósticos y predictivos del carcinoma de próstata en la biopsia prostática

Contact Info

Product

Resources

About